Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer

Scientific Reports(2024)10.1038/s41598-024-68338-2Source: DataRank Database

Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer is a research paper published in Scientific Reports (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.40)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Duncan Donohue ORCID,Tyler Malys,Jung‐Min Lee ORCID,Kristen R. Ibanez ORCID

Live enrichment

PubMed:39075200 PMC:PMC11286792 OpenAlex:https://openalex.org/W4401074352

National Institutes of Health

Grant: ZIA BC011525

National Institutes of Health

Grant: 1ZIABC011525-06

Leveraging DNA damage repair pathways as therapeutic targets in womens cancers

FWCI

0.40

Citation Percentile

0.7%

Citation Trend

2025

goldLicense: cc-by

journalhttps://www.nature.com/articles/s41598-024-68338-2.pdf

publisherhttps://www.nature.com/articles/s41598-024-68338-2.pdf

publisherhttps://www.nature.com/articles/s41598-024-68338-2

journalhttps://doi.org/10.1038/s41598-024-68338-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39075200

Fields of Study

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Genomics and Diagnostics0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Checkpoint Kinase 1Progression-Free SurvivalAdultAgedAged, 80 and overFemaleHumansMembrane ProteinsMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisPyrazinesPyrazolesBiomarkers, TumorCA-125 AntigenProtein Kinase InhibitorsResponse Evaluation Criteria in Solid Tumors

Keywords

MedicineInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyOvarian cancerConcordanceProgressive diseasePredictive markerBiomarkerCancerGastroenterologyDiseaseAdultScienceArticleBiomarkers, TumorHumansProtein Kinase InhibitorsAgedOvarian NeoplasmsAged, 80 and overQRMembrane ProteinsMiddle AgedPrognosisProgression-Free SurvivalCA-125 AntigenPyrazinesCheckpoint Kinase 1PyrazolesFemaleNeoplasm Recurrence, Local

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: No poverty